Tag: #oncology

FDA Expands IBRANCE Approval for Maintenance Treatment in HR+, HER2+ Metastatic Breast Cancer

FDA expands use of Pfizer’s IBRANCE (palbociclib) as maintenance therapy with trastuzumab and endocrine therapy for HR+, HER2+ metastatic breast cancer.

$PFE, #oncology, #breastcancer, #fda, #pharma

Pfizer’s Phase 3 Lung Cancer Drug Misses Overall Survival Goal; Stronger Trend in Second‑Line Patients

Pfizer's Phase 3 lung cancer trial of sigvotatug vedotin missed its overall survival goal; company sees a stronger trend in second‑line patients.

$PFE, #pfizer, #oncology, #lungcancer, #clinicaltrials

Pfizer’s BRAFTOVI Combo Shows Longer Progression-Free Survival in First-Line BRAF V600E Metastatic Colorectal Cancer

Phase 3 BREAKWATER Cohort 3 data show encorafenib plus cetuximab with FOLFIRI extended median PFS to 15.2 months vs. 8.3 months in control.

$PFE, #oncology, #colorectalcancer, #pfizer, #braftovi